Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission
Clinical & Translational Immunology · 2023-01 · 12 (3)
DOI: 10.1002/cti2.1439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 15.03.2023. Verfasst von Guillaume Dorcet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Département de Neurologie Hôpital Pierre Paul Riquet, CHU de Toulouse Toulouse France. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Because of its heterogeneity in clinical presentation and course, predicting autoimmune encephalitis (AIE) evolution remains challenging. Hence, our aim was to explore the correlation of several biomarkers with the clinical course of disease.
Methods
Thirty‐seven cases of AIE were selected retrospectively and divided into active ( N = 9), improved ( N = 12) and remission ( N = 16) AIE according to their disease evolution. Nine proteins were tested in both serum and cerebrospinal fluid (CSF) at diagnosis (T0) and during the follow‐up (T1), in particular activated MMP‐9 (MMP‐9A) and YKL‐40 (or chitinase 3‐like 1).
Results
From diagnosis to revaluation, AIE remission was associated with decreased YKL‐40 and MMP‐9A levels in the CSF, and with decreased NfL and NfH levels in the serum. The changes in YKL‐40 concentrations in the CSF were associated with (1) still active AIE when increasing >10% ( P‐ value = 0.0093); (2) partial improvement or remission when the changes were between +9% and −20% ( P‐ value = 0.0173); and remission with a reduction > −20% (P‐ value = 0.0072; overall difference between the three groups: P‐ value = 0.0088). At T1, the CSF YKL‐40 levels were significantly decreased between active and improved as well as improved and remission AIE groups but with no calculable threshold because of patient heterogeneity.
Conclusion
The concentration of YKL‐40, a cytokine‐like proinflammatory protein produced by glial cells, is correlated in the CSF with the clinical course of AIE. Its introduction as a biomarker may assist in following disease activity and in evaluating therapeutic response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Département de Neurologie Hôpital Pierre Paul Riquet, CHU de Toulouse Toulouse France.
- Laboratoire d'Immunologie Institut Fédératif de Biologie, CHU de Toulouse Toulouse France.
- INSERM, INFINITy Toulouse France.
- INSERM, ToNIC Toulouse France.
- Unité Pédiatrique Neuro-céphalique Hôpital des Enfants, CHU de Toulouse Toulouse France.
- Department of Chemistry University of South Florida Tampa FL USA.
ORCID-Profile: Guillaume Dorcet
Zitieren
APA
Dorcet, G., Benaiteau, M., Pariente, J., Ory-Magne, F., Cheuret, E., Rafiq, M., Brooks, W., Puissant-Lubrano, B., Fortenfant, F., Renaudineau, Y., & Bost, C. (2023). Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission. Clinical & Translational Immunology, 12(3). https://doi.org/10.1002/cti2.1439
Vancouver
Dorcet G, Benaiteau M, Pariente J, Ory-Magne F, Cheuret E, Rafiq M, et al. Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission. Clinical & Translational Immunology. 2023;12(3). doi:10.1002/cti2.1439
BibTeX
@article{Dorcet2023,
author = {Dorcet, Guillaume and Benaiteau, Marie and Pariente, Jérémie and Ory-Magne, Fabienne and Cheuret, Emmanuel and Rafiq, Marie and Brooks, Wesley and Puissant-Lubrano, Bénédicte and Fortenfant, Françoise and Renaudineau, Yves and Bost, Chloé},
title = {Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission},
journal = {Clinical & Translational Immunology},
year = {2023},
volume = {12},
number = {3},
doi = {10.1002/cti2.1439}
}
EUVIMED